Beximco Pharmaceuticals Limited Sponsored GDR RegS AI Stock Analysis
Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) AI Stock Analysis
Beximco Pharmaceuticals Limited Sponsored GDR RegS
(LSE:BXP)
No summary available
Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $256.51M
- Dividend Yield
- 7.52%
- Average Volume (3M)
- 22.80K
- Price to Earnings (P/E)
- 4.5
- Beta (1Y)
- -0.18
- Revenue Growth
- 3.86%
- EPS Growth
- 19.11%
- Country
- UK
- Employees
- 6,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Beximco Pharmaceuticals Limited Sponsored GDR RegS Business Overview & Revenue Model
Company Description
Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The fir...
Beximco Pharmaceuticals Limited Sponsored GDR RegS Peers Comparison
Overall Rating
GB:HIK74Outperform
GB:VLG65Neutral
GB:HLN63Neutral
GB:STX43Neutral
GB:AGY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | GBP 3.47B | 12.38 | 15.05% | 3.76% | 2.48% | 3.36% | |
| 65Neutral | GBP 82.26M | 15.82 | 7.82% | ― | ― | ― | |
| 63Neutral | GBP 30.09B | 18.92 | 9.89% | 1.34% | 1.21% | 8.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | GBP 32.76M | -4.09 | 64.57% | ― | 36.19% | 60.75% | |
| 38Underperform | GBP 88.66M | -1.59 | 1684.19% | ― | 8.77% | -7.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:BXP | Beximco Pharmaceuticals Limited Sponsored GDR RegS | 57.50 | 20.29 | 54.52% | |
| GB:AGY | Allergy Therapeutics | 1.40 | -7.40 | -84.09% | |
| GB:HIK | Hikma Pharmaceuticals | 1685.00 | 190.70 | 12.76% | |
| GB:STX | Shield Therapeutics | 3.05 | -3.70 | -54.81% | |
| GB:VLG | Venture Life | 69.00 | 10.00 | 16.95% | |
| GB:HLN | Haleon PLC | 343.20 | -19.06 | -5.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
